TOKYO, April 26, 2018 - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that it filed applications for its anti-coagulation factor IXa/X humanized bispecific monoclonal antibody / coagulation factor VIII substitute, “HEMLIBRA^® Subcutaneous Injection 30 mg, 60 mg, 90 mg, 105 mg, and 150 mg” [generic name: emicizumab (genetical recombination)] to the Ministry of Health, Labour and Welfare (MHLW) for an additional indication of prophylactic treatment for people with hemophilia A without inhibitors to factor VIII, as well as for additional dosage and administration as a biweekly or every four-week treatment for people with hemophilia A with inhibitors to factor VIII.

These filings are based on the results from HAVEN 3 study (NCT02847637) and HAVEN 4 study (NCT03020160). HAVEN 3 study is a global phase III study evaluating HEMLIBRA subcutaneous injection, once a week and once every two weeks, in people with hemophilia A (12 years of age or older) without inhibitors to factor VIII. HAVEN 4 study is a global phase III study evaluating efficacy, safety, and pharmacokinetics of HEMLIBRA subcutaneous injection every four weeks in people with hemophilia A (12 years of age or older), with and without inhibitors to factor VIII. Based on the results from these studies, the filings were submitted for two purposes including: 1) expansion of the indication to include weekly, biweekly, or every four-week subcutaneous treatment for people with hemophilia A without inhibitors to factor VIII; and 2) addition of dosage and administration to include the biweekly or every four-week subcutaneous treatment for people with hemophilia A with inhibitors to factor VIII for whom the weekly injection has previously been approved.

“HEMLIBRA has recently been designated as a Breakthrough Therapy from the U.S. Food and Drug Administration (FDA) for the treatment of hemophilia A without inhibitors to factor VIII. We are very glad that the filing to include this indication has been successfully submitted in Japan,” said Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit, Dr. Yasushi Ito. “The purpose of the two filings is to obtain approval for weekly, biweekly, and every four-week subcutaneous injections of HEMLIBRA regardless of the presence of inhibitors to factor VIII. Chugai is committed to seek approval so that we may deliver HEMLIBRA to people with hemophilia A without inhibitors as a new therapeutic option, as well as to further improve convenience for people with inhibitors by extending the dosing interval as soon as possible.”

Trademarks used or mentioned in this release are protected by law.

References

About the results of HAVEN 3 study
Press release issued on November 20, 2017
https://www.chugai-pharm.co.jp/english/news/detail/20171120151500_52.html

About the results of HAVEN 4 study
Press release issued on December 7, 2017
https://www.chugai-pharm.co.jp/english/news/detail/20171207150000_48.html

About the approval for HEMLIBRA for people with hemophilia A with factor VIII inhibitors in Japan
Press release issued on March 23, 2018
https://www.chugai-pharm.co.jp/english/news/detail/20180323150000_26.html

About Breakthrough Therapy Designation for the treatment of hemophilia A without factor VIII inhibitors in the U.S.
Press release issued on April 17, 2018
https://www.chugai-pharm.co.jp/english/news/detail/20180417140000_23.html